How Does Veoza Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Veoza Works
- Active ingredient: Fezolinetant – a first‑in‑class selective neurokinin 3 (NK3) receptor antagonist.
- Primary action: Blocks neurokinin B (NKB) from binding to NK3 receptors in the hypothalamus, stabilising the body’s temperature control centre.
- Onset & efficacy: Reduction in hot flashes and night sweats can be seen within 1 week; maximal effect is typically achieved by 4 weeks of once‑daily dosing.
- Metabolism: Extensively metabolised by CYP1A2 in the liver; half‑life ~8–10 hours.
- Non‑hormonal: Unlike hormone replacement therapy, Veoza does not contain oestrogens and works directly on the brain’s thermoregulatory pathway.
Veoza (fezolinetant) is a non‑hormonal medicine specifically developed to treat moderate‑to‑severe vasomotor symptoms (hot flashes and night sweats) associated with menopause. It works by rebalancing the brain’s temperature control centre without introducing oestrogens, making it a valuable option for women who cannot or prefer not to use hormone replacement therapy.
Important Safety Information
Do not take Veoza if you are pregnant, breastfeeding, or taking strong or moderate CYP1A2 inhibitors (e.g., fluvoxamine, enoxacin, mexiletine, or ethinyl oestradiol‑containing contraceptives). Seek immediate medical advice if you develop signs of liver problems (unexplained fatigue, yellowing of skin/eyes, dark urine) or if you experience a severe allergic reaction (swelling of face/lips, difficulty breathing).
Chemical Composition & Molecular Structure
Veoza film‑coated tablets contain the active substance fezolinetant. The molecular formula is C19H22FN5O2S, and it acts as a highly selective antagonist of the neurokinin 3 (NK3) receptor. The molecule is designed to cross the blood‑brain barrier efficiently, allowing it to reach its target in the hypothalamus.
Structural & Pharmaceutical Properties
Systematic IUPAC name
4-[(5R)-5-(fluoromethyl)-5-hydroxy-4,5-dihydro-1H-pyrazol-1-yl]benzonitrile – (but the full structure includes a sulfonamide moiety conferring NK3 selectivity).
Fezolinetant is a small molecule with a molecular weight of approximately 414 g/mol. It exhibits high lipophilicity (logP ~2.6), facilitating central nervous system penetration.
Tablet core & coating
Core: mannitol (E421), hydroxypropyl cellulose (E463), low‑substituted hydroxypropyl cellulose (E463a), microcrystalline cellulose (E460), magnesium stearate (E470b).
Film‑coating: hypromellose (E464), talc (E553b), macrogol (E1521), titanium dioxide (E171), iron oxide red (E172).
The red colour and debossing (“logo + 645”) ensure easy identification.
🗒️ Pharmaceutical insight: The tablet is designed for once‑daily oral administration with no food restrictions. The formulation ensures consistent bioavailability regardless of meal timing.
Mechanism of Action: NK3 Receptor Antagonism
Before menopause, oestrogen and the neuropeptide neurokinin B (NKB) work in balance to maintain a stable body temperature set‑point. As oestrogen levels fall during the menopausal transition, NKB signalling becomes unchecked, leading to excessive activation of NK3 receptors in the hypothalamus. This disrupts the thermoregulatory centre, triggering the characteristic hot flashes and night sweats.
Fezolinetant binds selectively and competitively to NK3 receptors, blocking NKB from binding. By dampening this overactive signalling pathway, the hypothalamus regains its ability to keep core body temperature stable. The result is a significant reduction in both the frequency and severity of vasomotor symptoms (VMS).
| Component | Role in Thermoregulation | Effect of Veoza |
|---|---|---|
| Neurokinin B (NKB) | Excitatory neurotransmitter that increases when oestrogen declines | Blocked from binding to NK3 receptors |
| NK3 receptors | Located in the hypothalamic thermoregulatory centre | Antagonised by fezolinetant |
| Hypothalamic set‑point | Becomes unstable with unopposed NKB | Stabilised, reducing hot flashes |
🔬 Clinical pharmacology note: Veoza does not interact with oestrogen, progesterone, or other sex hormone receptors. Its action is entirely central and non‑hormonal, making it suitable for women with contraindications to hormone replacement therapy.
Absorption & Distribution (Pharmacokinetics)
After oral administration, fezolinetant is rapidly absorbed. Maximum plasma concentrations (Cmax) are reached approximately 1–2 hours post‑dose. The absolute bioavailability is around 71%, and food does not significantly affect absorption.
Distribution
Fezolinetant has a large volume of distribution (≈150 L), indicating extensive tissue distribution, including penetration into the central nervous system. Plasma protein binding is moderate (~50%), primarily to albumin.
Steady State
With once‑daily dosing, steady‑state concentrations are reached after 5–7 days, with an accumulation ratio of approximately 1.5‑fold compared to a single dose.
The half‑life of fezolinetant is 8–10 hours, supporting once‑daily administration. No dose adjustment is required based on age, weight, or mild‑to‑moderate renal impairment (severe renal impairment has not been studied).
Metabolic Effects & Elimination
Fezolinetant is metabolised primarily by the cytochrome P450 enzyme CYP1A2, with minor contributions from CYP2C8 and CYP2C9. The major circulating metabolites are pharmacologically inactive or have negligible NK3 receptor activity. Concomitant use of strong or moderate CYP1A2 inhibitors (e.g., fluvoxamine, enoxacin, mexiletine, or ethinyl oestradiol‑containing contraceptives) can increase fezolinetant exposure by 2‑ to 10‑fold and is therefore contraindicated.
Elimination occurs mainly via the kidneys: approximately 80% of a dose is excreted in urine (mostly as metabolites) and 20% in faeces. Less than 1% of the dose is excreted unchanged in urine.
⚠️ Metabolic caution: Patients with pre‑existing liver disease should have liver enzyme monitoring before and during treatment. If ALT or AST elevations exceed 3× the upper limit of normal, discontinuation should be considered.
Clinical Efficacy in Reducing Hot Flashes
The efficacy of Veoza 45 mg once daily was demonstrated in two pivotal phase III randomised, double‑blind, placebo‑controlled trials (SKYLIGHT 1 and SKYLIGHT 2) involving over 1,000 menopausal women with moderate‑to‑severe vasomotor symptoms. Key results included:
- A statistically significant reduction in the frequency of hot flashes from baseline to week 4 and sustained through week 12.
- Improvement in the severity of hot flashes as early as week 1.
- Reduction in night‑time awakenings due to sweating, leading to improved sleep quality.
- Benefits maintained during a 52‑week extension study (SKYLIGHT 4).
Veoza is indicated for women with natural or surgical menopause who experience bothersome vasomotor symptoms. Unlike hormone replacement therapy, it does not carry risks of breast tenderness, endometrial hyperplasia, or venous thromboembolism associated with oestrogen use.
Veoza FAQs
How long does it take for Veoza to start working?
Many women notice a reduction in hot flash frequency within the first week of treatment. Maximal benefit is typically seen after 4 weeks of consistent once‑daily use.
Is Veoza safe for women with a history of breast cancer?
Veoza does not contain oestrogen and does not interact with oestrogen receptors. However, the safety in women with breast cancer has not been established; your doctor will assess your individual risk before prescribing.
Can I take Veoza with hormone replacement therapy (HRT)?
The combination of Veoza with HRT has not been studied. Your doctor will likely recommend one therapy at a time to avoid unnecessary medication and to monitor efficacy clearly.
What should I do if I miss a dose of Veoza?
If you remember within 12 hours of your scheduled time, take the missed dose as soon as possible. If it is less than 12 hours until your next dose, skip the missed dose and resume your normal schedule. Do not take a double dose.
Does Veoza cause weight gain or affect mood?
In clinical trials, weight gain was not reported as a common side effect. Mood changes were not significantly different from placebo; however, individual responses vary. Discuss any mood concerns with your doctor.
Need Veoza with Professional Guidance?
If you are struggling with troublesome hot flashes and night sweats, a UK‑registered doctor can assess your suitability for Veoza. This non‑hormonal option may offer relief without the risks associated with oestrogen‑based therapies.
Secure Prescription & Next‑Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors
Start Menopause ConsultationRelated Veoza Guides
Medical Content Manager
Nabeel is a co-founder and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co-founder and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 28 March 2026
Next Review: 28 September 2026
Published on: 28 March 2026
Last Updated: 28 March 2026